A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To facilitate provision of atovaquone (566C80) to patients who have mild to moderate
Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim /
sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80.
Phase:
N/A
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Atovaquone Trimethoprim, Sulfamethoxazole Drug Combination